Project Number: 5348-32000-016-00
Project Type: Appropriated

Start Date: Feb 13, 2001
End Date: Feb 12, 2006

Objective:
Determine the complete genomic sequence of Anaplasma marginale. Define genes expressed by Anaplasma marginale during infection of tick-vector midguts and salivary glands. Select appropriate A. marginale gene products and delivery system(s) for vaccine testing. Define the role of tick-vector genetics in the epidemiology of Anaplasma marginale.

Approach:
The focus of the current CRIS is vaccine development. We have completed sequencing and annotation of 25% of the 1.2-megabase genome. This genomic information is being utilized in two ways: 1) the genomic organization of previously identified major surface proteins of A. marginale is being defined and 2) we are in the discovery phase of identifying A. marginale genes expressed during different phases of its life cycle, particularly during tick infection. This information will be used to select A. marginale genes and gene products for vaccine studies. An important aspect of A. marginale epidemiology, which will determine eventual success of A. marginale control strategies, is the impact of tick vector genetics on A. marginale transmission. To that end, significant aspects of this research plan include defining genetic markers of tick vector competence and using these markers to examine vector capacity of species and populations of ticks in endemic regions. IBC approved 9-04-01; BSL-1.

Project Team

Knowles, Donald - Don Scoles, Glen Suarez, Carlos Goff, Willard - Will

Project Annual Reports

FY 2003   FY 2002   FY 2001

Related National Programs

Veterinary, Medical and Urban Entomology (104)   Animal Health (103)

Related Projects

Outer Membrane Protein Complex of Anaplasma Marginale, Use in Vaccine Development Through Genomics